BeiGene, Ltd. announced that the China National Medical Products Administration approved four applications for BRUKINSA (zanubrutinib), including two Supplemental New Drug Applications for treatment-na ve adults with chronic lymphocytic leukemia or small lymphocytic lymphoma and Waldenstr m's macroglobulinemia, and two Supplemental Applications for conversions from conditional approval to regular approval.